Assessment of Dermatologic Family Impact Scale in the Parents of Children With Psoriasis

NCT ID: NCT02796014

Last Updated: 2017-08-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

129 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-05-31

Study Completion Date

2017-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Dermatological Diseases Family Impact Scale (DeFIS) was developed to assess different aspects of health-related quality of life in the relatives of the patients with various skin diseases. The preliminary validation of this instrument was performed for the Turkish population. In the pilot study, this 15-item-questionnaire was shown to be easy to complete and score, and reliably help to evaluate the family members' quality of life.

Psoriasis is a chronic disease which can be expected to have a significant impact on the quality of life of the patients and parents/family members alike. In line with this assumption, previous studies demonstrated that psoriasis psychosocially affects not only the patients, but also their close relatives. The psoriasis family index has been developed in an effort to objectively measure the health-related quality of life of the family members of patients with psoriasis. Nevertheless, data regarding the health-related quality of life of the parents of pediatric patients with psoriasis in the Turkish population are relatively scarce.

In study, the investigators primarily aim to utilize DeFIS to assess the impact of childhood psoriasis on the quality of life of the patients' parents. Further, the investigators attempt to investigate the relation between the quality of life of the patients and their parents, and reveal disease characteristics which might influence the quality of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis Quality of Life

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pediatric patients diagnosed with psoriasis by the dermatologists within the study period

Exclusion Criteria

* Patients with an equivocal diagnosis
* Parents unable to complete the questionnaire
* Patients with a serious medical disorder or in an emergency condition
Minimum Eligible Age

3 Months

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bakirkoy Dr. Sadi Konuk Research and Training Hospital

OTHER_GOV

Sponsor Role collaborator

Haseki Training and Research Hospital

OTHER

Sponsor Role collaborator

Haydarpasa Numune Training and Research Hospital

OTHER

Sponsor Role collaborator

Istanbul Training and Research Hospital

OTHER_GOV

Sponsor Role collaborator

Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization

OTHER

Sponsor Role collaborator

Sisli Hamidiye Etfal Training and Research Hospital

OTHER

Sponsor Role collaborator

Istanbul Medeniyet University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

burak tekin

Dr, M.D.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Burak Tekin, M.D.

Role: PRINCIPAL_INVESTIGATOR

Istanbul Medeniyet University Goztepe Research and Training Hospital Department of Dermatology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Istanbul Medeniyet University Goztepe Research and Training Hospital

Istanbul, Kadikoy, Turkey (Türkiye)

Site Status

Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Istanbul, , Turkey (Türkiye)

Site Status

Haseki Training and Research Hospital

Istanbul, , Turkey (Türkiye)

Site Status

Haydarpasa Numune Training and Research Hospital

Istanbul, , Turkey (Türkiye)

Site Status

Istanbul Training and Research Hospital

Istanbul, , Turkey (Türkiye)

Site Status

Okmeydani Training and Research Hospital

Istanbul, , Turkey (Türkiye)

Site Status

Sisli Etfal Training & Research Hospital

Istanbul, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210-6. doi: 10.1111/j.1365-2230.1994.tb01167.x.

Reference Type BACKGROUND
PMID: 8033378 (View on PubMed)

Gurel MS, Yanik M, Simsek Z, Kati M, Karaman A. Quality of life instrument for Turkish people with skin diseases. Int J Dermatol. 2005 Nov;44(11):933-8. doi: 10.1111/j.1365-4632.2004.02225.x.

Reference Type BACKGROUND
PMID: 16336527 (View on PubMed)

Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995 Jun;132(6):942-9. doi: 10.1111/j.1365-2133.1995.tb16953.x.

Reference Type BACKGROUND
PMID: 7662573 (View on PubMed)

Basra MK, Sue-Ho R, Finlay AY. The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease. Br J Dermatol. 2007 Mar;156(3):528-38. doi: 10.1111/j.1365-2133.2006.07617.x.

Reference Type BACKGROUND
PMID: 17300244 (View on PubMed)

Eghlileb AM, Basra MK, Finlay AY. The psoriasis family index: preliminary results of validation of a quality of life instrument for family members of patients with psoriasis. Dermatology. 2009;219(1):63-70. doi: 10.1159/000209234. Epub 2009 Mar 13.

Reference Type BACKGROUND
PMID: 19295185 (View on PubMed)

Tadros A, Vergou T, Stratigos AJ, Tzavara C, Hletsos M, Katsambas A, Antoniou C. Psoriasis: is it the tip of the iceberg for the quality of life of patients and their families? J Eur Acad Dermatol Venereol. 2011 Nov;25(11):1282-7. doi: 10.1111/j.1468-3083.2010.03965.x. Epub 2011 Jan 17.

Reference Type BACKGROUND
PMID: 21241373 (View on PubMed)

Ganemo A, Wahlgren CF, Svensson A. Quality of life and clinical features in Swedish children with psoriasis. Pediatr Dermatol. 2011 Jul-Aug;28(4):375-9. doi: 10.1111/j.1525-1470.2010.01292.x. Epub 2011 Jul 8.

Reference Type BACKGROUND
PMID: 21736605 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://journal.turkderm.org.tr/jvi.aspx?pdir=turkderm&plng=tur&un=TURKDERM-27167

Development and preliminary validation of the dermatological family impact scale

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2016/0118

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.